Tuesday, November 24, 2015 7:30:16 PM
Series A & A-1 warrants, 12.32 mil are exercisable at $0.10 but cannot be exercised until Nov. 28th.
Series B & B-1 warrants, 24.64 mil, if not already exercised, expired on Aug. 20th. These were exercisable at $0.20.
Series C warrants, exercisable at $0.50, 14.64 Mil. Can’t find an expiration.
Series C-1 warrants, 10 mil. 5 mil were already exercised by Eastern Capital on June 17th.
Series D & D-1 warrants, 12.32 mil, are only exercisable if the Series B & B-1 warrants have been exercised. Exercisable at $0.75.
Series E & E-1 warrants, 12.32 mil, are only exercisable if the series C & C-1 warrants have been exercised. Exercisable at $1.25
According to the recent 424B3 filing, found here http://www.tapimmune.com/investors/financial-filings/ , there were 2,659,417 outstanding warrants at the beginning of this year and 86,730,975 more were issued. 29,639,995 warrants were exercised, at a weighted average price of $0.25, between the beginning of the year and Sept. 30th. We know that 5mil C-1’s were exercised, so we can subtract 5 mil from that number leaving 24,639,995 which is pretty much the exact number of B/B-1 warrants.
So from that filing I would have to assume that pretty much all of the B/B-1 warrants were exercised along with Eastern Capitals’ 5mil C-1’s.
As of the filing there were 59,546,497 warrants outstanding. Which happens to be the number of A/A-1, C, remaining C-1’S, D/D-1, & E/E-1 warrants. Plus the warrants that were already outstanding at the beginning of the year.
The 24.64 mil D/D-1 & E/E-1 are not even exercisable right now given their exercise prices and the fact that not all of the C/C-1 warrants have been exercised. At $0.75, if the B/B1 warrants were really exercised, the D/D-1 warrants become exercisable.
Currently there are 19.64 mil warrants that can be exercised and there have been for at least the end of September. On Nov. 28th the A/A-1’s become exercisable adding 12.32 mil totaling 31.96 mil warrants. These A/A-1 warrants will be a little more enticing to exercise given the $0.10 strike, but remember that 5 mil of these belong to Eastern Capital and are restricted from being sold right away even if Dart wanted to sell them which we all know he doesn’t.
Eastern Capital currently owns 20 mil shares of TPIV and 20 mil warrants between their series A-1, remaining C-1, D-1, & E-1 warrants as seen here, http://archive.fastedgar.com//20150929/AQZZE22C6222F2Z2222S22ZZ7V9FZ2KH6G72/ which equates to a beneficial ownership of 48.3%
Regardless of what happens come the 28th Dart wants to own his full 48.3%, and that would require the price being above $1.25 so when the series A/A-1 warrants are exercised, which I believe they all will be, we won’t be held down for long. With all the news we are expecting in December I wouldn't be worrying about any of the warrants.
Friends don't let friends place market orders
Recent MRKR News
- Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:47:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:39:13 PM
- Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/14/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:12:59 AM
- Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma • GlobeNewswire Inc. • 08/12/2024 11:00:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM